Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NRG Oncology
University Health Network, Toronto
University of Michigan Rogel Cancer Center
NRG Oncology
University of Texas Southwestern Medical Center
Mayo Clinic
Rutgers, The State University of New Jersey
University of Iowa
Mayo Clinic
Washington University School of Medicine
NRG Oncology
Ohio State University Comprehensive Cancer Center
Sun Yat-sen University
The Cleveland Clinic
First Affiliated Hospital of Fujian Medical University
New Mexico Cancer Research Alliance
Thomas Jefferson University
Thomas Jefferson University
NRG Oncology
University of Texas Southwestern Medical Center
Stanford University
Ann & Robert H Lurie Children's Hospital of Chicago
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
University of California, San Diego
Hackensack Meridian Health
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute, Naples
UNC Lineberger Comprehensive Cancer Center
Wake Forest University Health Sciences
Emory University
Menoufia University
Case Comprehensive Cancer Center
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
UNC Lineberger Comprehensive Cancer Center
Center Eugene Marquis
Jiangsu Cancer Institute & Hospital
Albert Einstein College of Medicine
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Nebraska
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHSU Knight Cancer Institute
Guilin Medical University, China
Wake Forest University Health Sciences
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mayo Clinic
University Hospital, Ghent
RTOG Foundation, Inc.
University of Wisconsin, Madison
Centre hospitalier de l'Université de Montréal (CHUM)